Hunan Dajiaweikang Pharmaceutical Industry: Announcement on Progress of External Guarantee
Hunan Dajiaweikang Pharmaceutical Industry: Announcement on the progress of external guarantees
Hunan Dajiaweikang Pharmaceutical Industry: 301126 Dajia Weikang Investor Relations Management Information 20240429
Dajia Weikang: Announcement on holding the 2023 Online Results Briefing
Hunan Dajiaweikang Pharmaceutical Industry: Special audit instructions on the 2023 non-operating capital occupation and other related capital transactions of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Hunan Dajiaweikang Pharmaceutical Industry: Verification report and special report on the annual storage and use of funds raised in 2023 of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Dajia Weikang: Report of Guojin Securities Co., Ltd. on the 2023 continuous supervision and training of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Dajia Weikang: Announcement on Renewal of the Accounting Firm
Dajia Weikang: Announcement on changes in accounting policies
Dagga Weikang: Supervisory Board Resolutions Announcement
Dajia Weikang: Guojin Securities Co., Ltd.'s 2023 regular on-site inspection report on Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Dajia Weikang: Announcement on the estimated amount of guarantee for 2024
Dajia Weikang: 2023 Independent Director Debriefing Report (Liu Shuping)
Dajia Weikang: The Board's Special Opinion on the Independent Director Assessment
Dajia Weikang: Guojin Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Dajia Weikang: Report on the work of the Supervisory Committee in 2023
Dajia Weikang: Special Report on the Deposit and Use of Funds Raised in 2023
Dajia Weikang: 2023 Independent Director Debriefing Report (Tang Zhi)
Dajia Weikang: Inspection Opinions of Guojin Securities Co., Ltd. on the 2023 Internal Control Evaluation Report of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Dajia Weikang: 2023 Independent Director Debriefing Report (Chen Hao)
No Data